Effects of Tocotrienol on Cardiovascular Risk Markers in Patients With Chronic Kidney Disease: A Randomized Controlled Trial
Tocotrienols, isomers of vitamin E, may provide an effective nutritional strategy to mitigate common cardiovascular risks such as dyslipidemia, inflammation, and oxidative stress in patients with chronic kidney disease (CKD). This double-blind, placebo-controlled, randomized clinical trial aimed to...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Journal of Nutrition and Metabolism |
| Online Access: | http://dx.doi.org/10.1155/jnme/8482883 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592910215806976 |
|---|---|
| author | Liana Trugilho Lívia Alvarenga Ludmila Cardozo Bruna Paiva Jessyca Brito Isis Barboza Jonatas Almeida Juliana dos Anjos Pramod Khosla Marcelo Ribeiro-Alves Denise Mafra |
| author_facet | Liana Trugilho Lívia Alvarenga Ludmila Cardozo Bruna Paiva Jessyca Brito Isis Barboza Jonatas Almeida Juliana dos Anjos Pramod Khosla Marcelo Ribeiro-Alves Denise Mafra |
| author_sort | Liana Trugilho |
| collection | DOAJ |
| description | Tocotrienols, isomers of vitamin E, may provide an effective nutritional strategy to mitigate common cardiovascular risks such as dyslipidemia, inflammation, and oxidative stress in patients with chronic kidney disease (CKD). This double-blind, placebo-controlled, randomized clinical trial aimed to evaluate the effects of a tocotrienol-rich fraction (TRF) supplementation (300 mg/day) on oxidative stress and inflammatory markers, including transcription factors in nondialysis (ND) and hemodialysis (HD) CKD patients for three months. Interleukin-6, tumor necrosis factor-α (IL-6 and TNF-α), C-reactive protein (CRP), lipid peroxidation, biochemical parameters, and transcription factors such as NRF2 and NF-κB mRNA expression were evaluated. Seventeen HD patients (9 in the placebo group, 8 in the TRF group) and 16 ND CKD patients (8 in the placebo group and 8 in the TRF group) completed the study. In HD patients, significant reductions were observed in LDL cholesterol (p=0.04) and total plasma cholesterol levels (p=0.01) after TRF intervention. CRP serum levels decreased significantly in ND CKD patients (p=0.05) after TRF supplementation. Transcription factors NRF2 and NF-κB mRNA expressions remained unaltered in both groups. This study suggests that TRF supplementation may mitigate dyslipidemia and inflammation, factors involved with increased cardiovascular risk, in CKD patients, with variations in efficacy between HD and ND patients. |
| format | Article |
| id | doaj-art-1fc1d5c5561144acb0de4a5fc2bc6da6 |
| institution | Kabale University |
| issn | 2090-0732 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Nutrition and Metabolism |
| spelling | doaj-art-1fc1d5c5561144acb0de4a5fc2bc6da62025-01-21T00:00:04ZengWileyJournal of Nutrition and Metabolism2090-07322025-01-01202510.1155/jnme/8482883Effects of Tocotrienol on Cardiovascular Risk Markers in Patients With Chronic Kidney Disease: A Randomized Controlled TrialLiana Trugilho0Lívia Alvarenga1Ludmila Cardozo2Bruna Paiva3Jessyca Brito4Isis Barboza5Jonatas Almeida6Juliana dos Anjos7Pramod Khosla8Marcelo Ribeiro-Alves9Denise Mafra10Graduate Program in Medical SciencesGraduate Program in Medical SciencesGraduate Program in Nutrition SciencesGraduate Program in Cardiovascular SciencesGraduate Program in Medical SciencesGraduate Program in Cardiovascular SciencesClinic Unit of ResearchGraduate Program in Cardiovascular SciencesDepartment of Nutrition and Food ScienceHIV/AIDS Clinical Research CenterGraduate Program in Medical SciencesTocotrienols, isomers of vitamin E, may provide an effective nutritional strategy to mitigate common cardiovascular risks such as dyslipidemia, inflammation, and oxidative stress in patients with chronic kidney disease (CKD). This double-blind, placebo-controlled, randomized clinical trial aimed to evaluate the effects of a tocotrienol-rich fraction (TRF) supplementation (300 mg/day) on oxidative stress and inflammatory markers, including transcription factors in nondialysis (ND) and hemodialysis (HD) CKD patients for three months. Interleukin-6, tumor necrosis factor-α (IL-6 and TNF-α), C-reactive protein (CRP), lipid peroxidation, biochemical parameters, and transcription factors such as NRF2 and NF-κB mRNA expression were evaluated. Seventeen HD patients (9 in the placebo group, 8 in the TRF group) and 16 ND CKD patients (8 in the placebo group and 8 in the TRF group) completed the study. In HD patients, significant reductions were observed in LDL cholesterol (p=0.04) and total plasma cholesterol levels (p=0.01) after TRF intervention. CRP serum levels decreased significantly in ND CKD patients (p=0.05) after TRF supplementation. Transcription factors NRF2 and NF-κB mRNA expressions remained unaltered in both groups. This study suggests that TRF supplementation may mitigate dyslipidemia and inflammation, factors involved with increased cardiovascular risk, in CKD patients, with variations in efficacy between HD and ND patients.http://dx.doi.org/10.1155/jnme/8482883 |
| spellingShingle | Liana Trugilho Lívia Alvarenga Ludmila Cardozo Bruna Paiva Jessyca Brito Isis Barboza Jonatas Almeida Juliana dos Anjos Pramod Khosla Marcelo Ribeiro-Alves Denise Mafra Effects of Tocotrienol on Cardiovascular Risk Markers in Patients With Chronic Kidney Disease: A Randomized Controlled Trial Journal of Nutrition and Metabolism |
| title | Effects of Tocotrienol on Cardiovascular Risk Markers in Patients With Chronic Kidney Disease: A Randomized Controlled Trial |
| title_full | Effects of Tocotrienol on Cardiovascular Risk Markers in Patients With Chronic Kidney Disease: A Randomized Controlled Trial |
| title_fullStr | Effects of Tocotrienol on Cardiovascular Risk Markers in Patients With Chronic Kidney Disease: A Randomized Controlled Trial |
| title_full_unstemmed | Effects of Tocotrienol on Cardiovascular Risk Markers in Patients With Chronic Kidney Disease: A Randomized Controlled Trial |
| title_short | Effects of Tocotrienol on Cardiovascular Risk Markers in Patients With Chronic Kidney Disease: A Randomized Controlled Trial |
| title_sort | effects of tocotrienol on cardiovascular risk markers in patients with chronic kidney disease a randomized controlled trial |
| url | http://dx.doi.org/10.1155/jnme/8482883 |
| work_keys_str_mv | AT lianatrugilho effectsoftocotrienoloncardiovascularriskmarkersinpatientswithchronickidneydiseasearandomizedcontrolledtrial AT liviaalvarenga effectsoftocotrienoloncardiovascularriskmarkersinpatientswithchronickidneydiseasearandomizedcontrolledtrial AT ludmilacardozo effectsoftocotrienoloncardiovascularriskmarkersinpatientswithchronickidneydiseasearandomizedcontrolledtrial AT brunapaiva effectsoftocotrienoloncardiovascularriskmarkersinpatientswithchronickidneydiseasearandomizedcontrolledtrial AT jessycabrito effectsoftocotrienoloncardiovascularriskmarkersinpatientswithchronickidneydiseasearandomizedcontrolledtrial AT isisbarboza effectsoftocotrienoloncardiovascularriskmarkersinpatientswithchronickidneydiseasearandomizedcontrolledtrial AT jonatasalmeida effectsoftocotrienoloncardiovascularriskmarkersinpatientswithchronickidneydiseasearandomizedcontrolledtrial AT julianadosanjos effectsoftocotrienoloncardiovascularriskmarkersinpatientswithchronickidneydiseasearandomizedcontrolledtrial AT pramodkhosla effectsoftocotrienoloncardiovascularriskmarkersinpatientswithchronickidneydiseasearandomizedcontrolledtrial AT marceloribeiroalves effectsoftocotrienoloncardiovascularriskmarkersinpatientswithchronickidneydiseasearandomizedcontrolledtrial AT denisemafra effectsoftocotrienoloncardiovascularriskmarkersinpatientswithchronickidneydiseasearandomizedcontrolledtrial |